Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
N Kramkimel, A Thomas-Schoemann, L Sakji… - Targeted …, 2016 - Springer
Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAF
V600-mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) …
V600-mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) …
[HTML][HTML] Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer
L Timmers, CCLM Boons, J Moes-Ten Hove… - Journal of cancer …, 2015 - Springer
Purpose Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-
small cell lung cancer. Understanding actual use of medication is essential for optimizing …
small cell lung cancer. Understanding actual use of medication is essential for optimizing …
Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival
GW Kim, JS Song, CM Choi, JK Rho, SY Kim, SJ Jang… - Lung cancer, 2015 - Elsevier
Objectives EGFR activating mutations have been recognized as the most important predictor
of response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, 20–30% of patients …
of response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, 20–30% of patients …
The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis
T Gong, J Liu, J Jiang, YF Zhai, CM Wu… - Cellular and Molecular …, 2019 - cellmolbiol.org
The role of serum lactate dehydrogenase (LDH) on the clinical outcomes of non-small cell
lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) tyrosine-kinase …
lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) tyrosine-kinase …
[HTML][HTML] Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status
D Wang, M Zhang, X Gao, L Yu - PLoS One, 2016 - journals.plos.org
The study objective was to retrospectively analyze the metabolic variables derived from 18 F-
fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography …
fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography …
[HTML][HTML] Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
AM Hopkins, A Shahnam, S Zhang… - Cancer Biology & …, 2019 - ncbi.nlm.nih.gov
Objective Several predictors of survival have been identified in EGFR-positive non-small cell
lung cancer (NSCLC) patients treated with first generation EGFR inhibitors. Prognostic …
lung cancer (NSCLC) patients treated with first generation EGFR inhibitors. Prognostic …
[PDF][PDF] Significance of circulating tumor cells in non-small-cell lung carcinoma
Y Wang, X Tan, L Dai, N Yang, T Liu, G Liang… - Int J Clin Exp …, 2017 - e-century.us
Background: Non-small-cell lung carcinoma (NSCLC) accounts for nearly 85% of all lung
cancers. To date, reliable predictive and prognostic factors for NSCLC are still needed …
cancers. To date, reliable predictive and prognostic factors for NSCLC are still needed …
[图书][B] The Effect of Extracellular Biophysical Cues on Cellular Signal Processing
G Ou - 2016 - search.proquest.com
Cell behavior is regulated by both internal and external signals. In early biological research,
studies into cell signaling focused on biochemical cues. However, in recent decades, the …
studies into cell signaling focused on biochemical cues. However, in recent decades, the …